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Long-term health benefi ts 
of appetite suppressants 
remain unproven
Benefícios dos inibidores de apetite 
à saúde a longo prazo permanecem 
sem comprovação
ABSTRACT
Because of the increasing prevalence of obesity, prevention and treatment of 
overweight has become a major public health concern. In addition to diet and 
exercise, drugs are needed for patients who failed to lose weight with behavioral 
treatment. The current article aimed to summarize recent concerns on the safety 
and effi cacy of appetite suppressants. Several appetite suppressants have been 
banned for safety reasons. In 2010, sibutramine was withdrawn from the market 
because a long-term study showed it increased the risks of cardiovascular 
events. So far no study with a suffi ciently large sample size has demonstrated 
that appetite suppressants can reduce morbidity and mortality associated with 
overweight. The withdrawal of sibutramine highlights that guidelines for the 
evaluation of weight control drugs must be more stringent, and studies on their 
long-term health benefi ts are needed prior to their marketing.
DESCRIPTORS: Appetite Depressants. Anti-Obesity Agents, adverse 
effects. Long-term Effect. Treatment Outcome. Obesity, prevention & 
control. Sibutramine. Drug safety. Weight-loss drugs.
RESUMO
O aumento da prevalência da obesidade tornou a prevenção e tratamento do 
sobrepeso importante desafi o para a Saúde Pública. Além da dieta e exercício, 
os medicamentos são necessários para pacientes que não conseguem perder 
peso com as mudanças comportamentais. O objetivo do artigo foi sumarizar as 
preocupações atuais com a segurança e efetividade de medicamentos inibidores 
do apetite. Vários anorexígenos foram banidos por razões de segurança. 
Em 2010, a sibutramina foi retirada do mercado porque um estudo de longa 
duração mostrou que ela aumentava o risco de eventos cardiovasculares. Até 
agora nenhum estudo com número expressivo de pacientes demonstrou que 
anorexígenos reduzem a morbi-mortalidade associada ao sobrepeso. A retirada 
da sibutramina do mercado mostra que diretrizes para avaliação de medicamentos 
anorexígenos devem ser mais rigorosas, e que estudos de longa duração sobre 
os benefícios para a saúde devem ser realizados antes da comercialização.
DESCRITORES: Depressores do Apetite. Agentes Anti-Obesidade, efeitos 
adversos. Efeitos a Longo Prazo. Resultado de Tratamento. Obesidade, 
prevenção & controle. Sibutramina. Segurança de medicamentos. 
Tratamento da obesidade.
Comentários
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During recent decades the prevalence of overweight 
(body mass index – BMI >25 kg/m2) and obesity (BMI 
>30 kg/m2) has steadily increased worldwide. It was 
recently reported that 33.8% of adults (≥20 years old) 
in the US, and 20% of adults in Europe are obese.1,a In 
Brazil, the prevalence of overweight and obesity have 
also soared, and a recent survey has estimated that nearly 
50% of the population (all ages, males and females) are 
over the “ideal” weight and at least 13% are obese.b 
Since overweight was shown to contribute to the devel-
opment and aggravation of chronic conditions such as 
type 2 diabetes, hypertension, cardiovascular diseases, 
and several types of cancer, prevention and treatment of 
obesity is today a major public health concern.10
The current article aimed to summarize recent concerns 
on the safety and effi cacy of appetite suppressants. In 
light of the recent withdrawal of sibutramine from the 
European and North American markets after being 
marketed for 13 years, it is emphasized that large 
controlled randomized clinical studies on long-term 
health benefi ts of anti-obesity drugs are required prior 
to marketing authorization.
PHARMACOLOGICAL TREATMENT OF OBESITY
The ultimate goal of any treatment of obesity is to 
prevent or mitigate morbid conditions associated with 
excess weight, and not only reduce weight or to achieve 
an “ideal” weight. Diet, exercise-based program and 
behavioral therapies are the fi rst choice options for 
the treatment of obesity. According to modern clinical 
guidelines, pharmacological therapies, together with 
diet and exercise, should only be considered for obese 
patients who had failed to respond to behavioral 
approaches alone, and have no major contraindications 
to the use of the drug of choice. It has been recom-
mended that drug treatment must be discontinued if the 
patient has a weight loss of less than 2 kg per month for 
the fi rst three months of pharmacotherapy.8,11
In principle, both metabolic and behavioral compo-
nents of body weight regulation are potential targets 
to pharmacology interventions, but anti-obesity drugs 
currently available include appetite suppressants and 
orlistat, an inhibitor of pancreatic lipase that decreases 
fat absorption in the gastrointestinal tract.
FLAWS OF PAST ANTI-OBESITY DRUGS
The search for an effective and safe pharmacological 
therapy for obesity has been so far frustrating. Many 
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a World Health Organization. Obesity. Geneva; 2011 [cited 2011 Mar 8]. Available from: www.euro.who.int/en/what-we-do/health-topics/
diseases-and-conditions/obesity
b Ministério da Saúde. Vigitel 2009. Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. Brasília; 
2010 [cited 2011 Mar 7]. (Série G. Estatística e Informação em Saúde). Available from: http://189.28.128.100/dab/docs/publicacoes/geral/
publicacao_vigitel_2009.pdf
weight-loss drugs, mostly appetite suppressants, have 
been withdrawn from the market in the past for safety 
reasons.2
The anorexic effects of amphetamines were found as 
early as the mid-1930s and amphetamine-like agents 
(e.g. dextroamphetamine, methamphetamine and 
others) became the fi rst widely used drugs to induce 
weight loss. However, the effectiveness of sympathomi-
metic agents as anti-obesity drugs has been questionable 
at best. Central nervous system stimulant and anorexic 
effects of amphetamine-like drugs are apparently 
inseparable, tolerance develops over a few weeks, 
overall weight loss is only modest or unsatisfactory, 
and it is known they do not help to develop healthy 
eating habits.13 Because of they have high potential for 
abuse and addiction, and neuropsychiatric (psychotic 
symptoms, restlessness, insomnia, and others) and 
cardiovascular (hypertension, arrhythmias, angina and 
others) side effects, the use of amphetamine-like drugs 
for weight control was banned, drastically restricted 
or discouraged worldwide in the 1960s and 1970s.5,13
Fenfl uramine and dexfenfl uramine are inhibitors of 
serotonin reuptake and storage that were introduced 
as anorexic drugs in 1973 and 1985, respectively. Both 
drugs and a combination of fenfl uramine and phen-
termine (known as “fen-phen”) were widely used as 
weight-loss drugs until 1997 when they were withdrawn 
from the market in the US, Europe and other countries 
after reports of valvular heart damage, apparently 
caused by a selective stimulation of 5-HT2B receptors 
on human cardiac valves, and concerns on their possible 
association with pulmonary hypertension.2,3,5,9
Rimonabant, an endocannabinoid receptor (subtype 
CB1) blocker, received marketing approval from the 
European Medicines Agency (EMA) in June 2006 
for treatment of obese or overweight (BMI >27 kg/
m2) patients with associated risk factors such as type 
2 diabetes or dyslipidemia. In Brazil, where it was 
popularly known as “stomach fat pill,” rimonabant 
was approved with similar indications in April 2007. 
It is noteworthy that the Brazilian Medicines Advisory 
Committee (CATEME) had recommended health 
authorities not to approve rimonabant marketing 
before clarifying concerns on an apparent drug-induced 
increased risk of depression. Shortly thereafter (June 
2007), the US Food and Drug Administration (FDA) 
advisory committee voted not to recommend this 
drug’s approval because of concerns of severe neuro-
psychiatric side effects. A reevaluation of safety data 
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from rimonabant phase III studies showed that this 
CB1 blocker was associated with an increased risk of 
depression, anxiety and suicide ideation.3,5 Rimonabant 
marketing approval was withdrawn by EMA because 
they considered the risks outweighed the drug’s benefi ts 
and, in the late 2008, the drug manufacturer announced 
that sales and clinical research studies of rimonabant 
would be stopped permanently worldwide.3
Benfl uorex, a fenfl uramine-derivative, was recently 
withdrawn (November 2009) from the market in France 
and other European, Asian and South American coun-
tries where it had been used since 1976 for treating 
patients with high blood levels of triglycerides and 
overweight plus type-2 diabetes. A cohort study 
including a million patients with diabetes revealed that 
Benfl uorex was signifi cantly associated with hospi-
talization for valvular heart disease during the 2-year 
follow-up after drug exposure.9,12
LONG-TERM SCOUT STUDY OF SIBUTRAMINE
Sibutramine is an inhibitor of serotonin and norepi-
nephrine (and to a lesser extent of dopamine) reuptake 
that was originally developed as an antidepressant 
and subsequently found to have anorexic properties 
as well. It was introduced into the market in 1997 at 
the time that fenfl uramine-related drugs were removed 
from the market, and thus it largely replaced them as 
the most widely used appetite suppressants. Together 
with diet and exercise, sibutramine causes an average 
weight loss of 5% to 8%, as compared with 2% to 
4% achieved with placebo only. Similarly to other 
appetite suppressants, weight loss is more marked 
during the fi rst weeks of sibutramine administration 
and patients regain approximately half of the weight 
lost when drug therapy is extended up to two years. 
Moreover, in almost all cases, the additional weight 
loss obtained with sibutramine is not maintained after 
drug treatment discontinuation.
Sibutramine treatment was shown to cause short-term 
reductions of LDL and triglycerides, but increases in 
diastolic blood pressure and pulse rates were found in 
at least two meta-analyses.4,7 One comparative clinical 
study also reported that, although inducing a reduction 
in body weight similar to that of orlistat in hyperten-
sive patients, sibutramine did not exhibit the same 
benefi cial effects on blood pressure.4 Almost a decade 
after drug marketing approval in the US and Europe, 
long-term cardiovascular safety and effi cacy of sibutra-
mine were examined in a clinical study (Sibutramine 
Cardiovascular Outcomes Trial – SCOUT). The 
SCOUT study involved 10,744 obese patients with 
preexisting cardiovascular disease, type 2 diabetes, or 
both.6 The results showed that sibutramine signifi cantly 
increased (by 16%) the risk of non-fatal myocardial 
infarction and stroke, although the study did not detect 
any changes in the incidence of cardiovascular deaths or 
deaths from any cause.6 The conclusions of the SCOUT 
study on cardiovascular outcomes were astonishing 
because pharmacological obesity treatment and any 
anti-obesity therapy are primarily intended to reduce 
morbidity and mortality associated with overweight. 
The results of the SCOUT study showed that, rather 
than reducing the risk, sibutramine in fact increased 
the risk of heart attack and stroke, and that treatment of 
obesity with this appetite suppressant was ineffective 
regarding cardiovascular outcomes.
Some physicians have argued that the SCOUT study 
investigated a particularly vulnerable subpopulation of 
obese patients with heart disease and/or type 2 diabetes, 
and that sibutramine would be safe for patients who 
did not have these comorbidities. However, these 
assumptions have not been challenged by any controlled 
study comparable in statistical power to the SCOUT 
study. Although there is certainly a higher risk for a 
subpopulation of obese individuals with preexisting 
comorbidities, asymptomatic patients and those who 
have undiagnosed cardiovascular diseases are at an 
increased risk as well. Overweight is a risk factor for 
cardiovascular disease and, in clinical practice, it can 
be diffi cult to reliably rule out patients with silent 
diseases who could be placed at risk with sibutramine. 
Nonetheless, the most important argument for recom-
mending the withdrawal from market instead of a 
risk mitigation approach is the clear indication that 
sibutramine was ineffective in reducing overweight 
comorbidities. If a drug lacks effi cacy, even a low risk 
seems unacceptable.
REDUCTIONS IN MORBIDITY AND 
MORTALITY AS LONG-TERM EFFICACY 
VARIABLES FOR ANTI-OBESITY DRUGS
Approximately 13 years passed before long-term 
clinical benefi ts of sibutramine were investigated by 
a post-marketing study involving a large number of 
subjects. If they were required by regulatory agencies 
for pre-marketing safety and effi cacy evaluation, large 
long-term controlled randomized studies (the SCOUT 
study had a 5-year duration) would certainly increase 
drug research & development costs and considerably 
delay a decision on marketing authorization.
According to current guidelines (FDA, EMA) for devel-
oping weight control products (anti-obesity drugs), it is 
required a primary effi cacy endpoint (phase III studies) 
of weight loss of at least 5% greater than placebo after 
a 12-month period. FDA additionally requires that 
the proportion of drug-treated subjects who lose ≥5% 
of baseline body weight is at least 35% and two-fold 
the percentage in the placebo group. EMA primary 
effi cacy endpoint is more stringent and requires a 
weight loss of at least 10% of baseline weight over one 
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year.c,d Additional effi cacy variables are the evaluation 
of effects of CNS-acting drugs on neuropsychiatric 
function, and lack of deleterious effects on cardiovas-
cular risk factors (EMA). Both agencies recommend 
secondary endpoints for assessing effi cacy such as 
blood pressure, pulse rate, lipids, fasting glucose, 
insulin, and EMA specifi cally recommends also ultra-
sensitive C-reactive protein, sleep apnea episodes, 
mechanical joint distress, infertility and psychosocial 
aspects (i.e., quality of life).c,d Evaluation of long-term 
health benefi ts of anti-obesity drugs, however, is not 
currently required by regulatory agencies for marketing 
approval. The EMA guideline suggests that morbidity 
and mortality may be measured directly as effi cacy 
variables, but points out that they can only be properly 
assessed in large clinical trials.c
The short-term effi cacy endpoints do not necessarily 
translate into long-term health benefi ts for overweight 
and obese patients. Sibutramine, for instance, met 
primary efficacy endpoint requirements in a pre-
marketing phase III study, but it did not reduce cardio-
vascular morbidity in the long-term SCOUT study.6
One-year clinical data are insuffi cient to demonstrate 
that anti-obesity drugs are effective and safe for longer 
use. Obesity is a chronic condition and, since body 
weight lost with pharmacotherapy is generally regained 
after anti-obesity drug discontinuation,8 patients are 
expected to take these medicines for years, or even for 
the rest of their lives.
CONCLUSIONS
The regulatory agencies face a dilemma regarding guide-
line requirements for safety and effi cacy of anti-obesity 
drugs. If guidelines are more stringent and evidence of 
long-term health benefi ts is required, manufacturers will 
have to deal with longer drug development timelines 
with higher costs, creating signifi cant uncertainty on 
fi nal approval for marketing. Today only one drug for 
long-term treatment of obesity (orlistat) is marketed 
in the US and Europe. Although there is a potentially 
huge and profi table market for this type of drug, much 
longer research & development timelines and greater 
uncertainty on the outcome of drug approval process 
are likely to discourage investments in new anti-obesity 
medications. On the other side, if large clinical trials on 
long-term effi cacy and safety are not required prior to 
marketing, new ineffective drugs, like sibutramine and 
other appetite suppressants, can be introduced into the 
market and be available for a long time.
c European Medicines Agency. Guideline on clinical evaluation of medicinal products used in weight control. London; 2007.
d Food and Drug Administration. Guidance for industry: developing products for weight management. Rockville; 2007[cited 2011 Mar 7]. 
Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071612.pdf
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